These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36951406)

  • 1. Key stakeholders' perspectives on providing oral pre-exposure prophylaxis as HIV-prevention standard of care in clinical trials in South Africa.
    Beesham I; Milford C; Joseph Davey DL; Smit J; Mansoor LE; Beksinska M
    Afr J AIDS Res; 2023 Apr; 22(1):18-26. PubMed ID: 36951406
    [No Abstract]   [Full Text] [Related]  

  • 2. Post-trial access to and use of pre-exposure prophylaxis in Durban, South Africa.
    Beesham I; Milford C; Smit J; Joseph Davey DL; Baeten JM; Heffron R; Beksinska M; Mansoor LE
    BMC Public Health; 2023 Jun; 23(1):1210. PubMed ID: 37349816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial.
    Beesham I; Heffron R; Evans S; Baeten JM; Smit J; Beksinska M; Mansoor LE
    AIDS Behav; 2021 Apr; 25(4):1112-1119. PubMed ID: 33106996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial.
    Beesham I; Welch JD; Heffron R; Pleaner M; Kidoguchi L; Palanee-Phillips T; Ahmed K; Baron D; Bukusi EA; Louw C; Mastro TD; Smit J; Batting JR; Malahleha M; Bailey VC; Beksinska M; Donnell D; Baeten JM;
    J Int AIDS Soc; 2020 May; 23(5):e25491. PubMed ID: 32396700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A qualitative study to explore daily versus on-demand oral pre-exposure prophylaxis (PrEP) in young people from South Africa, Uganda and Zimbabwe.
    Dietrich JJ; Ahmed N; Tshabalala G; Wu M; Mulaudzi M; Hornschuh S; Atujuna M; Muhumuza R; Ssemata AS; Stranix-Chibanda L; Nematadzira T; Bekker LG; Martinson N; Seeley J; Fox J
    PLoS One; 2023; 18(6):e0287627. PubMed ID: 37384792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily Oral Pre-exposure Prophylaxis (PrEP) Continuation Among Women from Durban, South Africa, Who Initiated PrEP as Standard of Care for HIV Prevention in a Clinical Trial.
    Beesham I; Joseph Davey DL; Beksinska M; Bosman S; Smit J; Mansoor LE
    AIDS Behav; 2022 Aug; 26(8):2623-2631. PubMed ID: 35122575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experiences of oral pre-exposure prophylaxis use among heterosexual men accessing sexual and reproductive health services in South Africa: a qualitative study.
    Cholo FA; Dada S; Martin CE; Mullick S
    J Int AIDS Soc; 2024 May; 27(5):e26249. PubMed ID: 38695102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motivations for pre-exposure prophylaxis uptake and decline in an HIV-hyperendemic setting: findings from a qualitative implementation study in Lesotho.
    Chebet JJ; McMahon SA; Tarumbiswa T; Hlalele H; Maponga C; Mandara E; Ernst K; Alaofe H; Baernighausen T; Ehiri JE; Geldsetzer P; Nichter M
    AIDS Res Ther; 2023 Jul; 20(1):43. PubMed ID: 37415180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Since both of us are using antiretrovirals, we have been supportive to each other": facilitators and barriers of pre-exposure prophylaxis use in heterosexual HIV serodiscordant couples in Kisumu, Kenya.
    Patel RC; Stanford-Moore G; Odoyo J; Pyra M; Wakhungu I; Anand K; Bukusi EA; Baeten JM; Brown JM
    J Int AIDS Soc; 2016; 19(1):21134. PubMed ID: 27964776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South Africa.
    Mansoor LE; Lewis L; Naicker CL; Harkoo I; Dawood H; Naidoo K; Gengiah TN; Samsunder N; Beesham I; Abdool Karim SS; Abdool Karim Q
    J Int AIDS Soc; 2022 Jul; 25(7):e25957. PubMed ID: 35785472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing the uptake of a mono-PrEP implant for the prevention of HIV: Males' perspectives from three South African provinces.
    Mthimkhulu N; Chidumwa G; Kutywayo A; Mataboge P; Martin CE; Kwatsha K; Makalela N; Mazibuko M; Butler V; Mullick S
    PLoS One; 2024; 19(1):e0296341. PubMed ID: 38166044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: results of a consultation with community stakeholders.
    Mack N; Odhiambo J; Wong CM; Agot K
    BMC Health Serv Res; 2014 May; 14():231. PubMed ID: 24886646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring Perceived Barriers and Facilitators of PrEP Uptake among Young People in Uganda, Zimbabwe, and South Africa.
    Muhumuza R; Ssemata AS; Kakande A; Ahmed N; Atujuna M; Nomvuyo M; Bekker LG; Dietrich JJ; Tshabalala G; Hornschuh S; Maluadzi M; Chibanda-Stranix L; Nematadzira T; Weiss HA; Nash S; Fox J; Seeley J
    Arch Sex Behav; 2021 May; 50(4):1729-1742. PubMed ID: 33954824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barriers and facilitators to pre-exposure prophylaxis uptake among male sex workers in Mexico: an application of the RE-AIM framework.
    Kadiamada-Ibarra H; Hawley NL; Sosa-Rubí SG; Wilson-Barthes M; Franco RR; Galárraga O
    BMC Public Health; 2021 Nov; 21(1):2174. PubMed ID: 34837988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake of and adherence to oral pre-exposure prophylaxis among adolescent girls and young women at high risk of HIV-infection in Kampala, Uganda: A qualitative study of experiences, facilitators and barriers.
    Kayesu I; Mayanja Y; Nakirijja C; Machira YW; Price M; Seeley J; Siu G
    BMC Womens Health; 2022 Nov; 22(1):440. PubMed ID: 36357920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study.
    Velloza J; Khoza N; Scorgie F; Chitukuta M; Mutero P; Mutiti K; Mangxilana N; Nobula L; Bulterys MA; Atujuna M; Hosek S; Heffron R; Bekker LG; Mgodi N; Chirenje M; Celum C; Delany-Moretlwe S;
    J Int AIDS Soc; 2020 Mar; 23(3):e25463. PubMed ID: 32144874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Client experiences with "Dynamic Choice Prevention," a model for flexible patient-centred HIV prevention delivery in rural Eastern Africa.
    Camlin CS; Arunga T; Johnson-Peretz J; Akatukwasa C; Atwine F; Onyango A; Owino L; Kamya MR; Petersen ML; Chamie G; Kakande E; Kabami J; Balzer LB; Havlir DV; Ayieko J
    J Int AIDS Soc; 2024 Jul; 27(7):e26336. PubMed ID: 39020454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial.
    Beesham I; Mansoor LE; Joseph Davey DL; Palanee-Phillips T; Smit J; Ahmed K; Selepe P; Louw C; Singata-Madliki M; Kotze P; Heffron R; Parikh UM; Wiesner L; Rees H; Baeten JM; Beksinska M
    J Acquir Immune Defic Syndr; 2022 Sep; 91(1):26-30. PubMed ID: 35972853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.
    Amico KR; Wallace M; Bekker LG; Roux S; Atujuna M; Sebastian E; Dye BJ; Elharrar V; Grant RM
    AIDS Behav; 2017 May; 21(5):1361-1375. PubMed ID: 27317411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perceptions of Pre-exposure Prophylaxis (PrEP) for HIV prevention among men living with HIV in the context of reproductive goals in South Africa: a qualitative study.
    Ntinga X; Isehunwa OO; Msimango LI; Smith PM; Matthews LT; Van Heerden A
    BMC Public Health; 2024 Feb; 24(1):553. PubMed ID: 38389039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.